Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer

Human Immunology

Volumn 60, Issue 6, 1999, Pages 510-515

  Ward, Robyn L ^a   Hawkins, Nicholas J ^b   Coomber, David ^a   Disis, Mary L ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibody; Colorectal cancer; HER 2 neu; Immunity; Tumor antigen

Indexed keywords

ANTIBODY; ONCOPROTEIN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; GENE OVEREXPRESSION; HUMAN; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2;

EID: 0033025229     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00003-8     Document Type: Article

References (17)

1. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J., Dodge R., Clarke-Pearson D., Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
2. Berchuck A., Rodriguez G., Kinney R.B., Soper J.T., Dodge R.K., Clarke-Pearson D.L., Bast R.C. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 164:1991;15-21.
3. neu expression in human lung adenocarcinomas predicts shortened survival. Ca Res. 50:1990;5184-5191.
4. Slamon D., Clark G., Wong S., Levin W., Ullrich A., McGuire W. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science. 235:1987;177-182.
5. Yonemura Y., Ninomiya I., Yamaguchi A., Fushida S., Kimura H., Ohoyama S., Miyazakil I., Endou Y., Tanaka M., Susaki T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognisis in gastric cancer. Ca Res. 51:1991;1034-1038.
6. Kay E., Mulcahy H., Walsh C., Leader M., O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology. 25:(5):1994;455-461.
7. Shirai H., Ueno E., Osaki M., Tatebe S., Ito H., Kaibara N. Expression of growth factors and their receptors in human early colorectal carcinomas immunohistochemical study . Anticancer Res. 15:(6B):1995;2889-2894.
8. Natali P., Nicotra M., Bigotti A., Venturo I., Slamon D., Fendly B., Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 45:(3):1990;457-461.
9. Disis M.L., Calenoff E., McLaughlin G., Murphy A.E., Chen W., Groner B., Jeschke M., Lydon N., McGlynn E., Livingston R.B., Moe R., Cheever M.A. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:1994;16-20.
10. Fisk B., Blevins T.L., Wharton J.T., Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 181:(6):1995;2109-2117.
11. Yoshino I., Goedegebuure P.S., Peoples G.E., Parikh A.S., DiMaio J.M., Lyerly H.K., Gazdar A.F., Eberlein T.J. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 54:(13):1994;3387-3390.
12. Disis M.L., Pupa S.M., Gralow J.R., Dittadi R., Menard S., Cheever M.A. High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol. 15:(11):1997;3363-3367.
13. Dukes C., Bussey H. The spread of rectal cancer and its effects on prognosis. Brit J Cancer. 12:1958;309-320.
14. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 14:(3):1996;737-744. [see comments].
15. Allred D., Clark G., Tandon A., Molina R., Tormey D., Osborne C., Gilchrist K., Mansour E., Abeloff M., Eudey L. HER-2/neu in node negative breast cancer prognostic significance of overexpression influenced by the presence of in situ carcinoma . J Clin Oncol. 10:(4):1992;599-605.
16. Qin H.L., Chen W., Takahashi M., Disis M.L., Byrd D.R., Fenton R., Bertram K., McCahill L., Peace D.J., Cheever M.A. CD4+ T cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res, Advances in Brief. 55:1995;2984-2987.
17. Takahashi M., Chen W., Byrd D., Disis M.L., Huseby E., McCahill L., Nelson H., Peace D., Qin H.L., Shimada H., Okuno K., Yasutomi M., Cheever M.A. Antibody responses to ras proteins in patients with colon cancer. Clin Cancer Res, Advances in Brief. 1:(10):1995;1071-1077.